Otsuka reports positive data from two Phase III ADHD treatment trials

Otsuka Pharmaceutical has reported positive data from two Phase III clinical trials of its investigational compound, centanafadine, to treat attention-deficit/hyperactivity disorder (ADHD).

The randomised, three-arm, double-blind, fixed-dose, six-week pivotal trials assessed the safety, efficacy and tolerability of centanafadine to treat ADHD in adolescents and children.